Celgene Corporation

Agios Pharmaceuticals, Inc.

Laurie A Kenvin

Kyle MacBeth

Samuel V Agresta

Jorge DiMartino

Robert Douglas Knight

Krishnan Viswanadhan

Vivek Saroj Kumar Chopra

Qiang Xu

Provided are methods and compositions for treating cancers in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and a DNA demethylating agent.

Combination therapy for treating malignancies

Provided are methods and compositions for treating hematological malignancies in patients carrying an IDH1 mutation using a combination of an inhibitor of mutant IDH1 enzyme, (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide, or a pharmaceutically acceptable salt thereof (COMPOUND 2) and a DNA demethylating agent.

Growing community of inventors

New Hope, PA, United States of America

Laurie A Kenvin